MapLight (MPLT) CFO awarded new RSUs and stock options with long-term vesting

Rhea-AI Filing Summary

MapLight Therapeutics Chief Financial Officer Vishwas Setia reported new equity awards. On February 5, 2026, he acquired 7,730 shares of voting common stock at $0, described as a restricted stock unit (RSU) award. One quarter of these RSUs will vest on January 1, 2027, with the remainder vesting in equal installments on each April 1, July 1, October 1 and January 1 thereafter, contingent on continued service.

Setia was also granted an employee stock option for 31,395 shares of voting common stock at an exercise price of $15.7 per share, expiring on February 4, 2036. One quarter of the option will vest on February 5, 2027, with the balance vesting monthly in equal installments, also subject to continued service. Following these awards, he directly holds 395,549 shares of voting common stock and 31,395 stock options.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Setia Vishwas

(Last) (First) (Middle)

C/O MAPLIGHT THERAPEUTICS, INC.

800 CHESAPEAKE DRIVE

(Street)

REDWOOD CITY CA 94063

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
MapLight Therapeutics, Inc. [ MPLT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/05/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Voting Common Stock	02/05/2026		A		7,730(1)	A	$0(2)	395,549	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$15.7	02/05/2026		A		31,395		(3)	02/04/2036	Voting Common Stock	31,395	$0	31,395	D

Explanation of Responses:

1. Represents a restricted stock unit ("RSU") award. 1/4th of the RSUs shall vest on January 1, 2027, and 1/16th of the RSUs shall vest on each subsequent April 1, July 1, October 1 and January 1 thereafter, subject to the Reporting Person's continued service through each vesting date.

2. Each RSU represents a contingent right to receive one share of voting common stock of the Issuer.

3. 1/4th of the total shares underlying the option shall vest on February 5, 2027, and 1/48th of the total shares shall vest each month thereafter on the same day of the month, subject to the Reporting Person's continued service through each vesting date.

	/s/ Kristopher L. Hanson, Attorney-in-Fact	02/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did MPLT CFO Vishwas Setia report on February 5, 2026?

Vishwas Setia reported receiving 7,730 shares of voting common stock through an RSU award and 31,395 employee stock options. Both awards vest over time and are contingent on his continued service with MapLight Therapeutics.

How do the new RSUs granted to MPLT CFO Vishwas Setia vest?

The RSU award vests 1/4 on January 1, 2027, with the remaining 3/4 vesting in 1/16 increments each April 1, July 1, October 1 and January 1 thereafter. Vesting requires Setia to remain in service through each date.

What are the key terms of the new employee stock options granted to MPLT’s CFO?

Setia received options for 31,395 shares of voting common stock with a conversion or exercise price of $15.7 per share. One quarter vests on February 5, 2027, and the rest vests monthly, with all vesting conditioned on his continued service.

How many MapLight Therapeutics shares does the CFO own after these transactions?

After the reported RSU acquisition, Setia directly holds 395,549 shares of voting common stock. He also beneficially owns 31,395 employee stock options, all reported as directly held in the filing.

Does each RSU granted to MPLT’s CFO equal one share of common stock?

Yes. Each restricted stock unit represents a contingent right to receive one share of MapLight Therapeutics voting common stock. Actual receipt depends on satisfaction of the specified vesting and continued service conditions.

When do the newly granted MPLT stock options to the CFO expire?

The employee stock options granted to Setia expire on February 4, 2036. Vesting occurs over several years, beginning February 5, 2027, but any unexercised options would terminate at the stated expiration date.